---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-005343"
form_type: "8-K"
ticker: "PMVP"
cik: "0001699382"
company_name: "PMV Pharmaceuticals, Inc."
filed_at: "2023-03-01T23:59:59+00:00"
generated_at: "2026-06-18T18:24:08.833261+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PMV Pharma reports FY2022 net loss $73.3M; cash $243.5M; PC14586 update expected 2H 2023

## Summary
- Net loss $73.3M in FY2022 vs $57.8M in FY2021; R&D expenses rose to $52.0M from $36.5M.
- Cash, equivalents, and marketable securities $243.5M at Dec 31, 2022, down from $314.1M.
- Phase 1/2 PYNNACLE study of PC14586 ongoing; first patient enrolled in combination arm with KEYTRUDA.
- WIP-1 and R273H programs put on hold; projected cash runway extended to 1H 2025.
- Appointed Kirsten Flowers and Carol Gallagher to Board; promoted Michael Carulli to SVP Finance.

## SEC filing metadata
- accession: 0000950170-23-005343
- form_type: 8-K
- ticker: PMVP
- cik: 0001699382
- company_name: PMV Pharmaceuticals, Inc.
- filed_at: 2023-03-01T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/0000950170-23-005343-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/pmvp-20230301.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-005343
- JSON: https://secwatch.observer/filing/0000950170-23-005343.json
- Plain text: https://secwatch.observer/filing/0000950170-23-005343.txt

## Key facts
- Earnings Releases
  PMV Pharmaceuticals, Inc. reported the full year ended December 31, 2022 results: net income Net loss for the year ended December 31, 2022, was $73.3 million.
  - Period: the full year ended December 31, 2022
  - Net income: Net loss for the year ended December 31, 2022, was $73.3 million
  - Result: reported results
  source text: Net loss for the year ended December 31, 2022, was $73.3 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1699382/000095017023005343/0000950170-23-005343-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.